{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T17:51:42Z","timestamp":1791049902114,"version":"4.1.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"11","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The effects of antiangiogenic therapy on tumors relapsing after irradiation are not known. To this end, we irradiated human tumors growing s.c. in nude mice with a single dose of 20 or 30 Gy. Compared with primary (treatment-naive) xenografts, the growth rate of recurrent tumors was 1.6-fold slower, which is consistent with the known \u201ctumor bed effect.\u201d For similar size tumors, recurrences had fewer functional vessels, a reduced vessel coverage by perivascular cells, and were more necrotic. Placenta growth factor concentration was significantly lower in relapses, whereas vascular endothelial growth factor (VEGF) levels were similar between primary and recurrent tumors. On the other hand, fibrillar collagen deposition was significantly increased in recurrent tumors. This radiation-induced fibrosis was partially responsible for the slower growth of recurrences; the i.t. injection of collagenase increased the growth rate of tumor relapses without affecting primary tumor growth. The mouse-specific VEGF receptor 2\u2013blocking antibody DC101 induced a 2.2-fold longer growth delay in recurrent tumors compared with treatment-naive tumors. DC101 significantly decreased the interstitial fluid pressure and did not change the functional vessel density and perivascular cell coverage in both tumor variants. Interestingly, DC101 induced a rapid (2 days after treatment initiation) and significant decrease in tumor cell proliferation in recurrent but not in primary tumors. Thus, our results show that the stromal compartment and the response to antiangionenic therapy of primary and in-field recurrent tumors are significantly different. Our findings suggest that antiangiogenic agents could be effective in the treatment of patients with relapses after radiotherapy. [Cancer Res 2007;67(11):5076\u201382]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-3664","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T22:28:14Z","timestamp":1180736894000},"page":"5076-5082","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Human Tumor Xenografts Recurring after Radiotherapy Are More Sensitive to Anti\u2013Vascular Endothelial Growth Factor Receptor-2 Treatment than Treatment-Naive Tumors"],"prefix":"10.1158","volume":"67","author":[{"given":"Sergey V.","family":"Kozin","sequence":"first","affiliation":[{"name":"1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Winkler","sequence":"additional","affiliation":[{"name":"1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Garkavtsev","sequence":"additional","affiliation":[{"name":"1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Hicklin","sequence":"additional","affiliation":[{"name":"2ImClone Systems, Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[{"name":"1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Boucher","sequence":"additional","affiliation":[{"name":"1Edwin L. Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"2022061623212678300_B1","doi-asserted-by":"crossref","unstructured":"Trott KR, Kummermehr J. Split dose recovery of a mouse tumour and its stroma during fractionated irradiation. Br J Radiol\u20081982; 55: 841\u20136.","DOI":"10.1259\/0007-1285-55-659-841"},{"key":"2022061623212678300_B2","unstructured":"Milas L, Milas M. Tumor bed phenomenon: effect of tumor progression and therapy. In: Rubin DB, editor. The radiation biology of the vascular endothelium. Boca Raton (FL): CRC Press; 1998. p. 209\u201329."},{"key":"2022061623212678300_B3","doi-asserted-by":"crossref","unstructured":"van Bree C, Schopman EM, Bakker PJ, Kipp JB, Barendsen GW. Local hyperthermic treatment does not enhance mitoxantrone effectiveness for responses of a rat solid tumour regrowing after irradiation. J Cancer Res Clin Oncol\u20081996; 122: 147\u201353.","DOI":"10.1007\/BF01366954"},{"key":"2022061623212678300_B4","doi-asserted-by":"crossref","unstructured":"Petersen C, Eicheler W, Baisch H, Zips D, Baumann M. Impact of preirradiation of the tumour bed on cell production rate and cell loss of human FaDu squamous cell carcinoma growing in nude mice. Int J Radiat Biol\u20081999; 75: 1293\u20137.","DOI":"10.1080\/095530099139458"},{"key":"2022061623212678300_B5","doi-asserted-by":"crossref","unstructured":"Beecken WD, Fernandez A, Joussen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst\u20082001; 93: 382\u20137.","DOI":"10.1093\/jnci\/93.5.382"},{"key":"2022061623212678300_B6","unstructured":"Folkman J, Heymach J, Kalluri R. Tumor angiogensis. In: Cancer medicine. 7th ed. 2006. p. 157\u201391."},{"key":"2022061623212678300_B7","unstructured":"Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res\u20082001; 61: 39\u201344."},{"key":"2022061623212678300_B8","doi-asserted-by":"crossref","unstructured":"Wang ES, Teruya-Feldstein J, Wu Y, Zhu Z, Hicklin DJ, Moore MA. Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood\u20082004; 104: 2893\u2013902.","DOI":"10.1182\/blood-2004-01-0226"},{"key":"2022061623212678300_B9","unstructured":"Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res\u20081999; 59: 3776\u201382."},{"key":"2022061623212678300_B10","doi-asserted-by":"crossref","unstructured":"Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res\u20081991; 51: 6691\u20134.","DOI":"10.1016\/B978-0-12-168561-4.50333-4"},{"key":"2022061623212678300_B11","unstructured":"Rosner BA. Fundamentals of biostatistics. 4th ed. Belmont: Duxbury Press; 1995."},{"key":"2022061623212678300_B12","unstructured":"Okunieff P, Dols S, Lee J, et al. Angiogenesis determines blood flow, metabolism, growth rate, and ATPase kinetics of tumors growing in an irradiated bed: 31P and 2H nuclear magnetic resonance studies. Cancer Res\u20081991; 51: 3289\u201395."},{"key":"2022061623212678300_B13","doi-asserted-by":"crossref","unstructured":"Zips D, Eicheler W, Geyer P, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res\u20082005; 65: 5374\u20139.","DOI":"10.1158\/0008-5472.CAN-04-3379"},{"key":"2022061623212678300_B14","doi-asserted-by":"crossref","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell\u20082007; 11: 83\u201395.","DOI":"10.1016\/j.ccr.2006.11.021"},{"key":"2022061623212678300_B15","unstructured":"Jirtle R, Clifton KH. Effect of preirradiation of the tumor bed on the relative vascular space of mouse gastric adenocarcinoma 328 and mammary adenocarcinoma CA755. Cancer Res\u20081973; 33: 764\u20138."},{"key":"2022061623212678300_B16","doi-asserted-by":"crossref","unstructured":"Runkel S, Hunter N, Milas L. An intradermal assay for quantification and kinetics studies of tumor angiogenesis in mice. Radiat Res\u20081991; 126: 237\u201343.","DOI":"10.2307\/3577824"},{"key":"2022061623212678300_B17","doi-asserted-by":"crossref","unstructured":"Taylor AP, Rodriguez M, Adams K, Goldenberg DM, Blumenthal RD. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer\u20082003; 105: 158\u201364.","DOI":"10.1002\/ijc.11059"},{"key":"2022061623212678300_B18","doi-asserted-by":"crossref","unstructured":"Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med\u20082001; 7: 575\u201383.","DOI":"10.1038\/87904"},{"key":"2022061623212678300_B19","doi-asserted-by":"crossref","unstructured":"Luttun A, Autiero M, Tjwa M, Carmeliet P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta\u20082004; 1654: 79\u201394.","DOI":"10.1016\/j.bbcan.2003.09.002"},{"key":"2022061623212678300_B20","unstructured":"Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res\u20082002; 62: 2749\u201352."},{"key":"2022061623212678300_B21","unstructured":"Znati CA, Rosenstein M, McKee TD, et al. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res\u20082003; 9: 5508\u201313."},{"key":"2022061623212678300_B22","doi-asserted-by":"crossref","unstructured":"Denham JW, Hauer-Jensen M. The radiotherapeutic injury\u2014a complex \u201cwound.\u201d Radiother Oncol\u20082002; 63: 129\u201345.","DOI":"10.1016\/S0167-8140(02)00060-9"},{"key":"2022061623212678300_B23","doi-asserted-by":"crossref","unstructured":"Anscher MS, Chen L, Rabbani Z, et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys\u20082005; 62: 255\u20139.","DOI":"10.1016\/j.ijrobp.2005.01.040"},{"key":"2022061623212678300_B24","doi-asserted-by":"crossref","unstructured":"Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol\u20081997; 15: 778\u201383.","DOI":"10.1038\/nbt0897-778"},{"key":"2022061623212678300_B25","doi-asserted-by":"crossref","unstructured":"Wall SJ, Werner E, Werb Z, DeClerck YA. Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen. J Biol Chem\u20082005; 280: 40187\u201394.","DOI":"10.1074\/jbc.M508226200"},{"key":"2022061623212678300_B26","doi-asserted-by":"crossref","unstructured":"Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med\u20082003; 9: 796\u2013800.","DOI":"10.1038\/nm879"},{"key":"2022061623212678300_B27","doi-asserted-by":"crossref","unstructured":"McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res\u20082006; 66: 2509\u201313.","DOI":"10.1158\/0008-5472.CAN-05-2242"},{"key":"2022061623212678300_B28","unstructured":"Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res\u20081999; 59: 5209\u201318."},{"key":"2022061623212678300_B29","doi-asserted-by":"crossref","unstructured":"Fenton BM, Paoni SF, Ding I. Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. Radiother Oncol\u20082004; 72: 221\u201330.","DOI":"10.1016\/j.radonc.2004.05.005"},{"key":"2022061623212678300_B30","doi-asserted-by":"crossref","unstructured":"Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res\u20082006; 66: 3639\u201348.","DOI":"10.1158\/0008-5472.CAN-05-3295"},{"key":"2022061623212678300_B31","doi-asserted-by":"crossref","unstructured":"Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol\u20082001; 18: 221\u20136.","DOI":"10.3892\/ijo.18.2.221"},{"key":"2022061623212678300_B32","doi-asserted-by":"crossref","unstructured":"Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res\u20082004; 64: 3731\u20136.","DOI":"10.1158\/0008-5472.CAN-04-0074"},{"key":"2022061623212678300_B33","doi-asserted-by":"crossref","unstructured":"Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the \u201cangiogenesis progression\u201d hypothesis. Eur J Cancer\u20081996; 32A: 2438\u201350.","DOI":"10.1016\/S0959-8049(96)00396-6"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/11\/5076\/2863113\/5076.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/11\/5076\/2863113\/5076.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:51:24Z","timestamp":1655434284000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/11\/5076\/533186\/Human-Tumor-Xenografts-Recurring-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,1]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-3664","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,1]]}}}